• 1
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002, June 10-12. HEPATOLOGY 2002; 36(Suppl): S3S20.
  • 2
    Strader DB, Wright W, Thomas DL, Seeff LB. AASLD Practice Guideline: Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 114771.
  • 3
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825832.
  • 4
    Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52: 574579.
  • 5
    Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24: 399413.
  • 6
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY 2002; 36(Suppl): S47S56.
  • 7
    Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130: 16791687.
  • 8
    Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. HEPATOLOGY 2000; 31: 241246.
  • 9
    Skinner HA, Sheu WJ. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 1982; 43: 11571170.
  • 10
    Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. HEPATOLOGY 2004; 39: 826834.
  • 11
    Bedossa P, for the French METAVIR Coorporative Group. Inter- and intra- observer variation in the assessment of liver biopsy of chronic hepatitis C. HEPATOLOGY 1994; 20: 1520.
  • 12
    Fayyad UM, Irani KB. Multi-interval discretization of continuous-valued attributes for classification learning. Proceedings of the 13th Int. Joint Conference on Artificial Intelligence 1993; 10221027.
  • 13
    Witten I, Frank E. Data Mining: Practical Machine Learning Tools and Techniques. 2nd edition. New York, NY: Elsevier, 2005.
  • 14
    Dash M, Liu H. Consistency-based Search in Feature Selection. Artificial Intelligence 2003; 151: 155276.
  • 15
    Liu H, Setiono R. A probabilistic approach to feature selection — A filter solution. In: 13th International Conference on Machine Learning (ICML'96). ICML1996; 319327.
  • 16
    DeLong, DeLong, Clarke-Pearson. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1998; 44: 837845.
  • 17
    Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598604.
  • 18
    Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231264.
  • 19
    Levine RA, Sanderson SO, Ploutz-Snyder R, Murray F, Kay E, et al. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006; 4: 12711277.
  • 20
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: A 20-year multicenter study. HEPATOLOGY 2000; 32: 9196.
  • 21
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562569.
  • 22
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon Alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 16661672.
  • 23
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 24
    Yang Q, Khoury MJ, Friedman J, Little J, Flanders WD. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 2005; 4: 11291137.
  • 25
    Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 22472250.
  • 26
    Murakami Y, Matsufuji S, Hayashi S, Tanahashi N, Tanaka K. Degradation of ornithine decarboxylase by the 26S proteasome. Biochem Biophys Res Commun 2000; 267: 16.
  • 27
    MacIntosh E, Gauthier T, Pettigrew N, Minuk G. Liver regeneration and the effect of exogenous putrescine on regenerative activity after partial hepatectomy in cirrhotic rats. HEPATOLOGY 1992; 16: 14281433.
  • 28
    Gan FY, Gesell MS, Moshier JA, Alousi M, Luk GD. Detection of ornithine decarboxylase messenger RNA in human hepatocellular carcinoma by in situ hybridization. Epithelial Cell Biol 1992; 1: 1317.
  • 29
    Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006; 130: 18861900.
  • 30
    Machida K, Cheng KT, Sung VM, Levine AM, Foung S, Lai MM. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol. 2006; 80: 866874.
  • 31
    Seki E, Osawa Y, Uchinami H, Brenner DA, Schwabe RF. TLR4 mediates inflammation and fibrogenesis after bile duct ligation [Abstract]. HEPATOLOGY 2005; 42: A265.
  • 32
    Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003; 38: 257265.
  • 33
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY. 2003; 38: 518526.
  • 34
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343350.